Virus-like Particle Vaccines and Platforms for Vaccine Development

Area of Science:

• Biotechnology
• Immunology
• Vaccinology

Background:

• Virus-like particles (VLPs) have emerged as a significant area of interest in vaccine development over the last two decades.
• Approved VLP-based vaccines demonstrate high efficacy and long-lasting immunity against hepatitis B virus (HBV), human papillomavirus (HPV), and hepatitis E virus (HEV).

Purpose of the Study:

• To review approved and developing VLP vaccines for human and veterinary applications.
• To summarize the development and pre-clinical testing of chimeric VLP vaccines.
• To highlight the advantages of VLP-based vaccines compared to conventional vaccine strategies.

Main Methods:

• Literature review of VLP vaccine research and development.
• Analysis of approved VLP vaccines and ongoing clinical trials.
• Summary of pre-clinical data for chimeric VLP vaccine candidates.

Main Results:

• Several VLP vaccines are approved and widely used, with others in development for various viral infections.
• Chimeric VLPs are being explored to enhance immunogenicity of foreign antigens for applications beyond infectious diseases, such as cancer.
• VLP platforms derived from diverse sources (human, animal, plant, bacterial viruses) offer versatility.

Conclusions:

• VLP vaccines provide a powerful platform for both stand-alone immunization and as carriers for foreign antigens, leading to chimeric VLP vaccines.
• VLP-based vaccines, including hybrid/mosaic variants, present significant advantages over traditional vaccine approaches like live-attenuated and inactivated vaccines.
• The versatility and efficacy of VLPs position them as a key technology in modern vaccinology for infectious diseases and beyond.